Clinical trials: PD-L1
Osteosarcoma, Neoadjuvant Therapy
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Given that osteosarcoma typically presents at an early age and predominantly affects pediatric and adolescent populations, early control of disease progression and the opportunity for complete tumor resection are particularly…
- Conditions
- Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy, PD-L1 Antibody
- Trial name
- NCT07142863
- Testing
- Envafolimab and neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation
The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.
- Trial name
- ImmunEO (NCT04609930)
- Testing
- Anti-PD-1 or anti-PD-L1
- Where
- France
- Volunteers
- 143 people
- Sponsor
- University Hospital, Montpellier